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A b s t r a c t
Background and aim: Subcutaneous implantable cardioverter-defibrillator (S-ICD) is an effective and modern tool used to 
protect patients at risk of sudden cardiac death (SCD) from potentially life-threatening ventricular arrhythmias. The first S-ICD 
systems were implanted in Poland in 2014, but since that time the national experience with that therapy has been limited. 
Our analysis summarises the single-centre experience at the Department of Cardiology and Electrotherapy of the Medical 
University of Gdansk with the use of S-ICD from the year 2014 to 2017. 
Methods and results: The S-ICD therapy was used in 12 patients (five male, seven female, mean age 57.2 ± 12.5 years), 
in eight of them for the secondary prevention of SCD. No surgical complications of implantation procedures were observed 
during the perioperative hospitalisation nor during follow-up. During the mean follow-up of 14 ± 13 months we observed 
the appropriate function of the systems and a ventricular fibrillation episode successfully terminated by the device in one 
patient, two cases of S-ICD sensing problems (one of which led to inadequate intervention of the device), and an episode of 
atrial fibrillation also leading to inadequate intervention in another patient. 
Conclusions: S-ICD, being an effective and safe method used to treat patients at risk of SCD, may be safely and successfully 
introduced into clinical practice in centres new to that field. The number of complications during the initial experience and 
introduction of that method may be kept low if the operating team is experienced enough in cardiac electrotherapy. 
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INTRODUCTION
Subcutaneous implantable cardioverter-defibrillator (S-ICD) is 
an effective and modern tool used to protect patients at risk of 
sudden cardiac death (SCD) from potentially life-threatening 
ventricular arrhythmias [1, 2]. The history of the device dates 
back to the years 2001–2004, when the first attempts were 
made in humans to determine the appropriate location of the 
body of the S-ICD device and the lead. The first implantations 
of the system in the current setting were performed in the years 
2008–2009 in New Zealand and Europe, in limited groups of 
patients (61 in total) [3]. Between 2010 and 2013, prospective 
clinical trials comprising 330 patients were conducted, and also 
some European centres were involved in that research [1]. The 
device acquired Food and Drug Administration approval in 
2012 [4]. The first S-ICD systems were implanted in Poland in 
the year 2014 [5, 6]. The number of procedures is increasing 
slowly, due to the high cost of the device and difficulties with 
reimbursement from the Polish national healthcare fund. The 
number of centres undertaking the effort to introduce this new 
technology is limited as well. As a consequence, there are only 
a few reports presenting the results of S-ICD use in Poland, 
especially single-centre ones. Our publication is intended to 
summarise the single-centre experience with the S-ICD use 
during the period from 2014 to 2017. 
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METHODS
At the Department of Cardiology and Electrotherapy of the 
Medical University of Gdansk, which is one of the referential 
centres in Poland, during the period from February 2014 to 
August 2017, S-ICD system therapy was used in 12 patients 
(five male, seven female, 34–69 years of age, mean age 
57.2 ± 12.5 years). Three patients received the Cameron 
Health model 1010 SQ-RX system, and the remaining — the 
Emblem Boston Scientific system. The first S-ICD related 
procedure in our clinic was at the same time the first S-ICD 
related procedure performed in Poland, and it was a repair 
procedure in a patient with an S-ICD implanted abroad (in 
the USA). During the repair procedure, which was performed 
due to imminent pocket decubitus, the location of the pocket 
was changed from subcutaneous to submuscular. A detailed 
description of that procedure was published elsewhere [7]. 
In the remaining 11 cases, a de-novo S-ICD implantation was 
performed. Demographic and clinical data of those 12 patients 
are summarised in Table 1. 
The S-ICD system was implanted for the secondary pre-
vention of SCD in eight patients, and primary prevention — in 
the remaining four patients. Additional factors favouring the 
decision to implant a subcutaneous system were: no vascular 
access due to unilateral or bilateral thrombosis of the subcla-
vian vein (three patients), high risk of future infective endocar-
ditis (IE; six patients), high risk of repeat failure of endocardial 
leads (three patients), previously implanted endocardial leads 
abandoned in the vascular system (three patients), and young 
age of the patient with long life expectancy (two patients). 
Clinical factors that were considered to put patients at high 
risk of IE comprised the following: the history of IE, dialysis, 
immunosuppression, and enterocutaneous stoma made in 
the course of oncological treatment, with a plan of further 
reconstructive procedures of the colon. The S-ICD system was 
the first system implanted in a given patient in five cases (of 
which in one patient the implantation of S-ICD was directly 
preceded by the implantation of a permanent epicardial VVI 
pacemaker during the same hospitalisation). In the remaining 
seven cases patients had had another device implanted previ-
ously — a transvenous ICD (T-ICD) (six patients) or a DDD 
pacemaker (one patient). Detailed indications for an S-ICD 
implantation are presented in Table 2.
All procedures were performed under general anaesthesia, 
and de-novo implantations were made with the use of the 
three-incision technique, with a subcutaneous device pocket 
in three patients and intramuscular pocket in the remaining 
patients (under the latissimus dorsi muscle). The decision to 
switch to the intramuscular pocket was associated with the 
growing experience of the implanting team, and personal 
opinion on the superiority of the latter location. In each case, 
limited fluoroscopy was used before the procedure to deter-
mine (and mark on the skin) the desired lead location, device 
location, and anatomical landmarks used to facilitate appropri-
ate selection of incision sites. A single, 65 J defibrillation test 
was performed directly following the implantation, unless any 
contraindication was found. In one case, the defibrillation test 
was skipped because of high risk associated with severe heart 
failure, and in one other case the test was postponed due to 
persistent atrial fibrillation (AF) to the next day, and it was pre-
ceded by transoesophageal echocardiographic examination. In 
that case, the S-ICD defibrillation test resulted in conversion 
to sinus rhythm. In 10 cases the induced ventricular fibrillation 
(VF) was terminated by the 65 J shock. In one case the 65 J 
shock was ineffective, and the test was repeated with a reverse 
polarity shock, which successfully terminated VF. No surgical 
complications of implantation procedures were observed during 
the perioperative hospitalisation. Patients were discharged with 
a setting of two detection windows: conditional shock zone 
180–230 bpm and non-conditional shock zone 220–240 bpm.
RESULTS
All patients are subject to post-operative periodic follow-up in 
our clinic. During the mean follow-up time of 14 ± 13 months 
(range: 1–41 months) we did not observe any abnormalities 
related to postoperative wounds, or any surgical complications 
(including lead or device migration) related to the implanted 
system. Follow-up device interrogation confirmed appropriate 
function of the systems. In one patient the device recorded 
four episodes of non-sustained polymorphic ventricular tachy-
cardia (VT), with no shock and spontaneous termination of 
the arrhythmia into sinus rhythm. The analysis of data stored 
by the devices revealed a VF episode successfully terminated 
by the device in one patient, two other cases of S-ICD sensing 
issues in two separate patients (one of which led to inadequate 
intervention of the device), and one episode of AF in another 
patient, also leading to inadequate intervention. No incident 
of clinically significant bradycardia was observed during the 
follow-up.
Analysis of the episodes stored  
by the S-ICD devices 
In patient JR we found a record of an inadequate interven-
tion during the first 24 h post-implantation due to sensing 
disturbances (Fig. 1). The reason for those was probably air 
that was not squeezed out from the device connector at im-
plantation, despite the fact that the lead was connected to 
the device according to the manufacturer’s instructions (the 
torque wrench has to be inserted into the connector prior to 
the lead). Another possible explanation of that phenomenon 
was contact between the lead tip and the metal suture placed 
on the sternum during prior cardiac surgery. Because of the 
inability to determine the cause of the sensing issues (lead 
contact with metal sutures was excluded with high prob-
ability based on the X-ray analysis), after consultation with 
a representative of the manufacturer, we decided to change 
the detection vector from the initial setting of secondary to 
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primary. No other sensing issues were observed during further 
13-month follow-up of that patient.
In patient ZR an inadequate intervention was recorded 
during the third month post implantation, due to AF with 
a very fast ventricular rate, exceeding the detection rate of 
the non-conditional shock zone (220 bpm), and varying QRS 
morphology (Fig. 2). In that case we modified detection set-
tings of the device from 200/220 bpm to 220/240 bpm and 
intensified the antiarrhythmic treatment. No other issues were 
recorded during the further five months of follow-up.
In patient RZ an episode of sensing disturbances was 
recorded in the 14th month after implantation, where a tran-
sient change of the QRS morphology resulted in reduction 
of the R-wave and increase of the amplitude of the T-wave 
(Fig. 3). Despite that abnormality, there was no intervention 
of the S-ICD. Transient bundle branch block was assumed 
to be the reason for the observed QRS morphology change. 
Such a phenomenon could not be re-induced during clini-
cal observation (including body movements, S-ICD device 
movement, physical exercise), and thus, having consulted 
the patient with a manufacturer’s representative, we did not 
change any of the detection settings of the device and left 
the standard gain and the secondary sensing vector. During 
the following five months of observation we did not record 
any further S-ICD sensing problems.
In patient BS, an episode of VF was recorded, adequately 
detected and treated by the device (Fig. 4).
In patient AM four episodes of non-sustained polymor-
phic VT (6–13 s) were recorded, which were appropriately 
detected by the device, and self-terminated without any 
high-voltage therapy (Fig. 5). 
DISCUSSION
Subcutaneous ICD is a modern tool that is increasingly applied 
to treat patients at risk of SCD. According to the European 
Society of Cardiology guidelines, S-ICD is recommended 
as an alternative to T-ICD systems, when there is no need 
to introduce permanent cardiac pacing, resynchronisation 
therapy, or antitachycardia pacing. A specific subpopulation of 
patients who may benefit from S-ICD therapy according to the 
guidelines are patients with difficult vascular access, patients 
Figure 1. Episode of sensing disturbances with a following 
inadequate intervention of the subcutaneous implantable 
cardioverter-defibrillator 
Figure 2. Inadequate subcutaneous implantable cardioverter-
-defibrillator intervention due to atrial fibrillation with fast 
ventricular rate
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after extraction of previous ICD systems due to infection, and 
young patients with long life expectancy [8]. In each patient 
in our cohort, at least one of the above guideline-derived 
indications was present. The efficacy and safety of S-ICD 
use was confirmed in prospective clinical trials [9, 10]. The 
results of those trials prove that the risk of implantation-related 
complications is low and equals approximately 1%, while the 
device-related complications occur in about 0.5% of patients 
during the first 30 days post-implantation. In our cohort of 
patients we did not observe any periprocedural surgical com-
plications, and in one of the patients an inadequate S-ICD 
shock, as described above, was reported. Literature data 
concerning long-term follow-up show that during two years 
of follow-up the incidence of complications increases by up 
to 10% [9]. In late post-operative follow-up the only adverse 
event in our cohort of patients was an inadequate shock due 
to AF with fast ventricular rhythm, which occurred in one of 
the patients three months after implantation. This may be due 
to the very low incidence of adverse effects, given that fact 
that the experience of our centre is limited (to 12 patients). As 
a comparison, in the EFFORTLESS study population supraven-
tricular tachycardias led to inadequate interventions in 1.5% 
of patients during the first year of follow-up, and that number 
increased to 2.3% during the following two years [11]. Other 
authors describing patient populations of a similar limited size, 
and a relatively short follow-up reported a higher percentage 
of complications, mainly of surgical nature, associated with 
delayed wound healing or local infection. This type of com-
plications was not observed in patients primarily implanted in 
our centre, but we reported one such event in a patient with 
a system implanted in another centre [12, 13]. Based on the 
available data, the initial experience of any centre and the first 
dozen or so procedures is associated with increased risk of any 
complications, and only after 13 procedures the performance 
stabilises [14]. An interesting phenomenon caught in the act 
in our study was a transient S-ICD sensing problem in one 
of the patients, probably due to a transient bundle branch 
block. That phenomenon was described by Sousa et al. [15]. 
In our patient though, those sensing abnormalities could not 
be re-induced in a controlled clinical setting and therefore 
(because we could not confirm the nature of the problem) 
we did not change the settings of the device.
Figure 3. Sensing disturbances in the subcutaneous  
implantable cardioverter-defibrillator system resulting  
from the transient bundle branch block
Figure 4. Episode of ventricular fibrillation adequately  
detected and treated by the subcutaneous implantable 
cardioverter-defibrillator system
Figure 5. Episode of non-sustained polymorphic ventricular 
tachycardia. No therapy from the subcutaneous implantable 
cardioverter-defibrillator, the arrhythmia terminated by itself. 
Normal function of the device
www.kardiologiapolska.pl
Maciej Kempa et al.
458
The low number of patients in our cohort and relatively 
short duration of follow-up of some of the patients are clear 
limitations of the above analysis. The aim of the analysis, 
however, was to present the initial experience of the operating 
team with the new treatment method in a single centre, and 
not to compare data with high-volume centres. 
CONCLUSIONS
Subcutaneous ICD, being an effective and safe method used 
to treat patients at risk of SCD, may be safely and successfully 
introduced into clinical practice in centres new to that field. 
The number of complications during the initial experience and 
introduction of that method may be kept low if the operating 
team is experienced enough in cardiac electrotherapy. 
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